Residues Within the Alpha Subunit Sequence 304-322 of Muscle Acetylcholine Receptor Forming Autoimmune CD4+ Epitopes in BALB/c Mice

Overview

Journal Immunology

Specialty Allergy & Immunology

Date 1994 May 1

PMID 7519170

Authors

P I Karachunski

N Ostlie

M Bellone

Affiliations

Soon will be listed here.

Abstract

BALB/c mice develop myasthenic symptoms after immunization with rodent acetylcholine receptor (AChR). After immunization with Torpedo AChR (TAChR), their CD4+ cells become strongly sensitized against a conserved region of the TAChR alpha subunit sequence (residues alpha 304-322), and cross-react vigorously with the homologous sequences of mouse and human AChR, which are almost identical. Therefore AChR-specific potentially autoreactive CD4+ cells exist in this strain. We immunized BALB/c mice with the synthetic TAChR sequence alpha 304-322. The CD4+ cells thus sensitized responded to TAChR, indicating that they recognize an epitope(s) produced upon TAChR processing. They recognized peptide alpha 304-322 in association with the I-Ad molecule. Anti-alpha 304-322 CD4+ cells cross-reacted well with the corresponding murine and human synthetic sequences. To identify residues involved in formation of an autoimmune epitope(s), CD4+ cells from mice immunized with peptide alpha 304-322 were challenged in vitro with single residue glycine-substituted analogues of this sequence. Substitution of residue W311, and of any residue within the sequence alpha 313-319 (RKVFIDT), consistently and, in some cases, strongly affected the CD4+ cells response. Substitution of residues in the region alpha 311-319 had variable effects in different experiments, and in general affected moderately the CD4+ response. These results suggest that anti-alpha 304-322 CD4+ cells comprise several clones, recognizing overlapping epitopes which share residues alpha 311-319. The importance of the sequence region alpha 311-319 for formation of CD4+ cell epitope(s) was verified by testing CD4+ cells sensitized to T alpha 304-322 with analogues of this sequence, carrying non-conservative substitutions at positions Q310, K314 and D318. Substitution of Q310 had minimal or no effects, while those of K314 or D318 strongly affected the CD4+ cell response.

References

Schmidt J, RAFTERY M . A simple assay for the study of solubilized acetylcholine receptors. Anal Biochem. 1973; 52(2):349-54. DOI: 10.1016/0003-2697(73)90036-5. View

Bellone M, Ostlie N, Karachunski P, Manfredi A . Cryptic epitopes on the nicotinic acetylcholine receptor are recognized by autoreactive CD4+ cells. J Immunol. 1993; 151(2):1025-38. View

Elliott J, Dunn S, Blanchard S, RAFTERY M . Specific binding of perhydrohistrionicotoxin to Torpedo acetylcholine receptor. Proc Natl Acad Sci U S A. 1979; 76(6):2576-9. PMC: 383650. DOI: 10.1073/pnas.76.6.2576. View

Christadoss P, Lennon V, Krco C, LAMBERT E, David C . Genetic control of autoimmunity to acetylcholine receptors: role of Ia molecules. Ann N Y Acad Sci. 1981; 377:258-77. DOI: 10.1111/j.1749-6632.1981.tb33737.x. View

Christadoss P, Lindstrom J, Talal N . Cellular immune response to acetylcholine receptors in murine experimental autoimmune myasthenia gravis: inhibition with monoclonal anti-I-A antibodies. Cell Immunol. 1983; 81(1):1-8. DOI: 10.1016/0008-8749(83)90205-8. View

Heinrikson R, Meredith S . Amino acid analysis by reverse-phase high-performance liquid chromatography: precolumn derivatization with phenylisothiocyanate. Anal Biochem. 1984; 136(1):65-74. DOI: 10.1016/0003-2697(84)90307-5. View

Engel A . Myasthenia gravis and myasthenic syndromes. Ann Neurol. 1984; 16(5):519-34. DOI: 10.1002/ana.410160502. View

Christadoss P, Lindstrom J, Melvold R, Talal N . Mutation at I-A beta chain prevents experimental autoimmune myasthenia gravis. Immunogenetics. 1985; 21(1):33-8. DOI: 10.1007/BF00372239. View

Levinson A, Zweiman B, Lisak R . Immunopathogenesis and treatment of myasthenia gravis. J Clin Immunol. 1987; 7(3):187-97. DOI: 10.1007/BF00915723. View

10.

GAMMON G, Shastri N, Cogswell J, Wilbur S, Krzych U, Miller A . The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev. 1987; 98:53-73. DOI: 10.1111/j.1600-065x.1987.tb00519.x. View

11.

Lindstrom J, Shelton D, Fujii Y . Myasthenia gravis. Adv Immunol. 1988; 42:233-84. DOI: 10.1016/s0065-2776(08)60847-0. View

12.

Sette A, Buus S, Appella E, Smith J, Chesnut R, Miles C . Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A. 1989; 86(9):3296-300. PMC: 287118. DOI: 10.1073/pnas.86.9.3296. View

13.

Protti M, Manfredi A, Straub C, Howard Jr J . Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. Proc Natl Acad Sci U S A. 1990; 87(19):7792-6. PMC: 54834. DOI: 10.1073/pnas.87.19.7792. View

14.

GAMMON G, Geysen H, Apple R, PICKETT E, Palmer M, Ametani A . T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J Exp Med. 1991; 173(3):609-17. PMC: 2118818. DOI: 10.1084/jem.173.3.609. View

15.

Bellone M, Ostlie N, Lei S, Wu X . The I-Abm12 mutation, which confers resistance to experimental myasthenia gravis, drastically affects the epitope repertoire of murine CD4+ cells sensitized to nicotinic acetylcholine receptor. J Immunol. 1991; 147(5):1484-91. View

16.

Bellone M, Ostlie N, Lei S . Experimental myasthenia gravis in congenic mice. Sequence mapping and H-2 restriction of T helper epitopes on the alpha subunits of Torpedo californica and murine acetylcholine receptors. Eur J Immunol. 1991; 21(10):2303-10. DOI: 10.1002/eji.1830211003. View

17.

Martin R, Utz U, Coligan J, Richert J, Flerlage M, Robinson E . Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106. J Immunol. 1992; 148(5):1359-66. View

18.

Nanda N, Arzoo K, Sercarz E . In a small multideterminant peptide, each determinant is recognized by a different V beta gene segment. J Exp Med. 1992; 176(1):297-302. PMC: 2119295. DOI: 10.1084/jem.176.1.297. View

19.

Feldmann M, June C, McMichael A, Maini R, Simpson E, Woody J . T-cell-targeted immunotherapy. Immunol Today. 1992; 13(3):84-5. DOI: 10.1016/0167-5699(92)90146-X. View

20.

Jaulin C, Casanova J, Romero P, Luescher I, Cordey A, Maryanski J . Highly diverse T cell recognition of a single Plasmodium berghei peptide presented by a series of mutant H-2Kd molecules. J Immunol. 1992; 149(12):3990-4. View